This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes.

Autor:	Ryder, Robert EJ., Holman, Rury R., Gwilt, Mike
Předmět:	CARDIOVASCULAR diseases risk factors TYPE 2 diabetes WEIGHT gain TREATMENT effectiveness GLYCEMIC control SULFONYLUREAS THERAPEUTICS
Zdroj:	British Journal of Diabetes & Vascular Disease; Apr-Jun2016, Vol. 16 Issue 2, p88-92, 5p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu